

# Hisashi Harada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/475257/publications.pdf>

Version: 2024-02-01

87  
papers

17,538  
citations

61984

43  
h-index

91884

69  
g-index

87  
all docs

87  
docs citations

87  
times ranked

20448  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
2	Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL. <i>Cell</i> , 1996, 87, 619-628.	28.9	2,444
3	Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. <i>Nature</i> , 1986, 324, 73-76.	27.8	2,028
4	Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN- $\beta$ gene regulatory elements. <i>Cell</i> , 1988, 54, 903-913.	28.9	991
5	Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. <i>Cell</i> , 1989, 58, 729-739.	28.9	965
6	Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. <i>Science</i> , 1994, 263, 1612-1615.	12.6	814
7	Phosphorylation and Inactivation of BAD by Mitochondria-Anchored Protein Kinase A. <i>Molecular Cell</i> , 1999, 3, 413-422.	9.7	593
8	Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-1-encoded p40x and T3/Ti complex triggering. <i>Cell</i> , 1987, 48, 343-350.	28.9	498
9	Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. <i>Cell</i> , 1994, 77, 829-839.	28.9	494
10	Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. <i>Science</i> , 1993, 259, 971-974.	12.6	451
11	Deletion of <i>IRF-1</i> , Mapping to Chromosome 5q31.1, in Human Leukemia and Preleukemic Myelodysplasia. <i>Science</i> , 1993, 259, 968-971.	12.6	398
12	Absence of the type I IFN system in EC cells: Transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. <i>Cell</i> , 1990, 63, 303-312.	28.9	381
13	Mcl-1 Down-regulation Potentiates ABT-737 Lethality by Cooperatively Inducing Bak Activation and Bax Translocation. <i>Cancer Research</i> , 2007, 67, 782-791.	0.9	366
14	Involvement of the IRF-1 transcription factor in antiviral responses to interferons. <i>Science</i> , 1994, 264, 1921-1924.	12.6	292
15	Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15313-15317.	7.1	263
16	An Shp2/SFK/Ras/Erk Signaling Pathway Controls Trophoblast Stem Cell Survival. <i>Developmental Cell</i> , 2006, 10, 317-327.	7.0	222
17	Essential and nonredundant roles of p48 (ISGF3 $\beta$ ) and IRF $\beta$ 1 in both type I and type II interferon responses, as revealed by gene targeting studies. <i>Genes To Cells</i> , 1996, 1, 115-124.	1.2	215
18	Cyanidin-3-rutinoside, a Natural Polyphenol Antioxidant, Selectively Kills Leukemic Cells by Induction of Oxidative Stress. <i>Journal of Biological Chemistry</i> , 2007, 282, 13468-13476.	3.4	185

#	ARTICLE	IF	CITATIONS
19	Essential role of BAX,BAK in B cell homeostasis and prevention of autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11272-11277.	7.1	181
20	Activation of a cell-cycle-regulated histone gene by the oncogenic transcription factor IRF-2. Nature, 1995, 377, 362-365.	27.8	179
21	The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie, 1998, 80, 641-650.	2.6	124
22	Regulation of the interferon system and cell growth by the IRF transcription factors. Journal of Cancer Research and Clinical Oncology, 1995, 121, 516-520.	2.5	118
23	Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1288-96.	7.1	110
24	Tumor cell escape from therapy-induced senescence. Biochemical Pharmacology, 2019, 162, 202-212.	4.4	105
25	Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Cancer Cell, 2016, 29, 159-172.	16.8	104
26	GX15-070 (obatoclox) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death and Disease, 2010, 1, e76-e76.	6.3	98
27	Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. Clinical Cancer Research, 2018, 24, 360-369.	7.0	96
28	The human interleukin-2 receptor $\beta$ -chain gene: genomic organization, promoter analysis and chromosomal assignment. Nucleic Acids Research, 1990, 18, 3697-3703.	14.5	91
29	Clearance of therapy-induced senescent tumor cells by the senolytic ABT263 via interference with BCL2-XL/BAX interaction. Molecular Oncology, 2020, 14, 2504-2519.	4.6	90
30	Regulation of IFN $\gamma$ /IFN $\beta$ genes: evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFN $\gamma$ /IFN $\beta$ . Genes To Cells, 1996, 1, 995-1005.	1.2	88
31	p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells. FEBS Letters, 2006, 580, 3539-3544.	2.8	86
32	OSU-03012 Promotes Caspase-Independent but PERK-, Cathepsin B-, BID-, and AIF-Dependent Killing of Transformed Cells. Molecular Pharmacology, 2006, 70, 589-603.	2.3	80
33	A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089. Autophagy, 2014, 10, 2346-2361.	9.1	79
34	Cell Cycle Regulation of Histone H4 Gene Transcription Requires the Oncogenic Factor IRF-2. Journal of Biological Chemistry, 1998, 273, 194-199.	3.4	78
35	The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood, 2009, 114, 4507-4516.	1.4	77
36	Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer. Cell Death and Disease, 2014, 5, e1052-e1052.	6.3	63

#	ARTICLE	IF	CITATIONS
37	Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells. <i>Cell Death and Disease</i> , 2012, 3, e349-e349.	6.3	56
38	MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. <i>Blood</i> , 2007, 109, 4006-4015.	1.4	55
39	Death and Survival Signals Determine Active/Inactive Conformations of Pro-apoptotic BAX, BAD, and BID Molecules. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 1999, 64, 343-350.	1.1	55
40	p53-independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells. <i>Molecular Oncology</i> , 2018, 12, 788-798.	4.6	52
41	MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. <i>Leukemia</i> , 2009, 23, 1744-1754.	7.2	50
42	Assignment of the human interferon regulatory factor-1 (IRF1) gene to chromosome 5q23-q31. <i>Genomics</i> , 1991, 10, 1097-1099.	2.9	48
43	Possible involvement of the transcription factor ISGF3 $\beta$ in virus-induced expression of the IFN- $\beta$ gene. <i>FEBS Letters</i> , 1995, 358, 225-229.	2.8	44
44	MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. <i>Blood</i> , 2007, 110, 2092-2101.	1.4	43
45	Yet Another Function of p53: The Switch That Determines Whether Radiation-Induced Autophagy Will Be Cytoprotective or Nonprotective: Implications for Autophagy Inhibition as a Therapeutic Strategy. <i>Molecular Pharmacology</i> , 2015, 87, 803-814.	2.3	43
46	Sequence of a cDNA coding for human IRF-2. <i>Nucleic Acids Research</i> , 1989, 17, 8372-8372.	14.5	40
47	FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program. <i>Molecular Therapy</i> , 2021, 29, 2583-2600.	8.2	39
48	17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 618-632.	4.1	38
49	Paclitaxel-Induced Apoptosis Is BAK-Dependent, but BAX and BIM-Independent in Breast Tumor. <i>PLoS ONE</i> , 2013, 8, e60685.	2.5	38
50	Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target. <i>Clinical Cancer Research</i> , 2018, 24, 5658-5672.	7.0	38
51	Apoptosis regulators. <i>Reviews in Clinical and Experimental Hematology</i> , 2003, 7, 117-38.	0.1	38
52	Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2016, 17, 27-35.	3.4	33
53	Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells. <i>Experimental Hematology</i> , 2009, 37, 151-158.	0.4	26
54	Solution structure of the IRF-2 DNA-binding domain: a novel subgroup of the winged helix-turn-helix family. <i>Structure</i> , 1998, 6, 491-500.	3.3	23

#	ARTICLE	IF	CITATIONS
55	Coamplification of <i>miR-4728</i> protects <i>HER2</i> -amplified breast cancers from targeted therapy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2594-E2603.	7.1	23
56	DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex. Oncotarget, 2016, 7, 36353-36365.	1.8	23
57	Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1. Carcinogenesis, 2009, 30, 1336-1344.	2.8	21
58	Targeting the Regulatory Machinery of BIM for Cancer Therapy. Critical Reviews in Eukaryotic Gene Expression, 2012, 22, 117-129.	0.9	21
59	Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy. Biochemical Pharmacology, 2021, 193, 114765.	4.4	20
60	Secondary structure and folding topology of the DNA binding domain of interferon regulatory factor 2, as revealed by NMR spectroscopy. FEBS Letters, 1995, 359, 184-188.	2.8	17
61	Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment. PLoS ONE, 2019, 14, e0219398.	2.5	17
62	Restoration of p53 Functions Protects Cells from Concanavalin A-Induced Apoptosis. Molecular Cancer Therapeutics, 2010, 9, 471-479.	4.1	16
63	TLR-dependent Bim phosphorylation in macrophages is mediated by ERK and is connected to proteasomal degradation of the protein. International Immunology, 2006, 18, 1749-1757.	4.0	14
64	Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin. Molecular Pharmacology, 2022, 101, 168-180.	2.3	13
65	Targeting Stress-Response Pathways and Therapeutic Resistance in Head and Neck Cancer. Frontiers in Oral Health, 2021, 2, 676643.	3.0	7
66	The impact of genetic background and Bid on the phenotype of Bcl-2-deficiency in mice. Apoptosis: an International Journal on Programmed Cell Death, 2008, 13, 53-62.	4.9	6
67	Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA. Cancers, 2021, 13, 2310.	3.7	6
68	A case of Juvenile polyposis localized in the stomach accompanied by anemia and hypoproteinemia. Progress of Digestive Endoscopy, 2001, 59, 52-55.	0.0	3
69	Abstract A23: Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer.. Clinical Cancer Research, 2014, 20, A23-A23.	7.0	1
70	Abstract 3082: Deficient NOXA in HER2-amplified breast cancer drives kinase inhibitor resistance. , 2017, , ,		1
71	Two Step Activation of the Interleukin-2 Autocrine Loop May be Involved in ATL Development. , 1987, , 161-169.		1
72	Unique Structure of the DNA Binding Domain of Interferon Regulatory Factor 2 Determined by NMR Spectroscopy.. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 1994, 70, 200-204.	3.8	0

#	ARTICLE	IF	CITATIONS
73	A case of gastrointestinal lipomatosis coexistent with metastatic tumors. Progress of Digestive Endoscopy, 2002, 60, 54-55.	0.0	0
74	A case of benign esophageal stricture of unknown origin. Progress of Digestive Endoscopy, 2002, 61, 74-75.	0.0	0
75	p38-MAP Kinase Activation Followed by BIM Induction Is Critical for Glucocorticoid-Induced Apoptosis in Lymphoblastic Leukemia Cells.. Blood, 2006, 108, 1382-1382.	1.4	0
76	Abstract 5579: Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor.. , 2013, , .		0
77	Regulation of Cell Growth by Transcription Factors, IRF-1 and IRF-2. , 1994, , 201-212.		0
78	IRF-1 Functions as a Tumor Suppressor. , 1995, , 77-88.		0
79	Abstract 1013: Understanding the molecular pathways underlying radio-sensitization of non-small cell lung cancer (NSCLC) by vitamin D (EB1089). , 2015, , .		0
80	Abstract 998: Induction of non-protective autophagy by radiation in tumor cells: Implications for autophagy inhibition as a therapeutic strategy. , 2015, , .		0
81	Abstract 1657: The role of Noxa/MCL-1 axis in solid tumors treated with DNA damaging agents. , 2015, , .		0
82	Abstract 2524: Combination with vorinostat overcomes ABT-263 resistance of small cell lung cancer. , 2015, , .		0
83	Abstract 2981: DNA damaging agent-induced apoptosis is controlled by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex. , 2016, , .		0
84	Abstract 2127: p53-independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in HNSCC cells. , 2017, , .		0
85	Sensitivity and Resistance to BH3 Mimetics in Cancer Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 147-180.	0.1	0
86	Abstract B31: A protein synthesis switch underlies initial survival of EGFR-mutant lung cancer to EGFR inhibitors. , 2018, , .		0
87	Abstract 901: Elimination of senescent tumor cells by ABT263 interferes with proliferative recovery and provides a two-hit therapeutic approach. , 2019, , .		0